Serum ICAM-1 as a Predictor of Prognosis in Patients with Acute Ischemic Stroke

Biomed Res Int. 2021 Mar 18:2021:5539304. doi: 10.1155/2021/5539304. eCollection 2021.

Abstract

Objective: Inflammation is one of the key mechanisms involved in functional impairment after stroke. Intercellular adhesion molecule-1 (ICAM-1) is an important inflammatory molecule in the body. The purpose of our study was to determine the correlation between ICAM-1 and the prognosis of acute ischemic stroke (AIS).

Methods: 286 AIS patients treated at Beijing Tiantan Hospital were continuously included in the study. The demographic data of the patients were collected, and the fasting blood within 24 hours of admission was collected to detect the clinical indicators. The functional prognosis was measured using the modified Rankin Scale (mRS) 3 months after stroke. The poor prognosis is defined as mRS ≥ 3. The enzyme-linked immunosorbent assay (ELISA) was used to determine the serum ICAM-1 levels.

Results: The serum ICAM-1 levels of patients with poor prognosis were significantly higher than that of patients with good prognosis (144.2 ± 14.8 vs 117.5 ± 12.1 pg/ml). Receiver operating characteristic curve (ROC) analysis showed that the sensitivity and specificity of serum ICAM-1 for predicting the prognosis of AIS were 74% and 76%, respectively. In logistic regression analysis, the serum ICAM-1 level is still an independent predictor of poor prognosis (odds ratio [OR]: 0.52; 95% confidence interval [CI]: 0.318-0.839).

Conclusions: Higher serum ICAM-1 levels on admission in AIS patients might increase the risk of poor prognosis.

Publication types

  • Clinical Trial

MeSH terms

  • Acute Disease
  • Aged
  • Female
  • Humans
  • Intercellular Adhesion Molecule-1 / blood*
  • Ischemic Stroke / blood*
  • Ischemic Stroke / diagnosis
  • Male
  • Middle Aged
  • Prognosis

Substances

  • ICAM1 protein, human
  • Intercellular Adhesion Molecule-1